Skip to main content

Table 5 Treatment and clinical data at last follow-up

From: Phenotypic characterization of X-linked hypophosphatemia in pediatric Spanish population

Patient Phosphorus element dose (mg/kg/day) Vitamin D dose (µg/day) Nephrocalcinosis
I.1 38a 0.50c No
I.2 40a 0.50c No
II.1 86a 1.20d Yes
III.1
IV.1 83a 0.60d No
IV.2 62a 1.00d No
V.1
VI.1
VII.1 No
VII.2
VII.3 55b 0.50c Yes
VII.4 52b 0.50c Yes
VIII.1 90a 1.50d Yes
IX.1
X.1 40a 0.25d No
XI.1 83a 0.50c No
XII.1 44b 0.29d No
XIII.1 41b 0.25c Yes
XIV.1 52a 1.20d
XV.1 41b 1.00c No
XVI.1
XVII.1 45b 0.25c Yes
XVIII.1
XIX.1 27b 0.50c Yes
XX.1 32a 0.50c No
XXI.1 63a 1.50d No
XXII.1
XXIII.1 65a 1.10d No
XXIV.1
XXV.1 38a 1.40c
XXVI.1 58b 0.25c No
XXVII.1 48b 0.60d No
XXVII.2
XXVIII.1
XXVIII.2
XXIX.1 0.10d No
XXX.1
XXX.2 Yes
XXXI.1
XXXII.1
XXXIII.1 49b 0.75c No
XXXIV.1
XXXV.1
XXXV.2
XXXVI.1
XXXVII.1
XXXVIII.1
XXXIX.1
  1. aPhosphate was administered as a solution
  2. bPhosphate was administered as tablets
  3. cCorresponds to 1,25 dihydroxy vitamin D
  4. dCorresponds to 1 hydroxy vitamin D